Sigma Planning Corp’s Lineage Cell Therapeutics LCTX Stock Holding History

Sigma Planning Corp’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$9.7K	Buy	+10,115	New	+$11.2K	﹤0.01%	1323

Other funds holding LCTX

Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Fifth Third Bancorp Cincinnati, Ohio $61.2B AUM 25.19% 1-Year Est. Return

Hofer & Associates Thousand Oaks, California $143M AUM 11.29% 1-Year Est. Return

Red Crane Wealth Management San Francisco, California $143M AUM 13.63% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Williams Jones Wealth Management New York $8.94B AUM 17.99% 1-Year Est. Return

Sigma Planning Corp's LCTX Position: Q3 2026 in Review

Sigma Planning Corp opened a new position in Lineage Cell Therapeutics (LCTX) in Q3 2026: 10,115 shares worth $9.7K. The stake represents ﹤0.01% of the portfolio and ranks #1323 among its holdings.

57 funds tracked by Wall St. Rank hold LCTX as of Q3 2026.

Sigma Planning Corp held 10,115 shares of Lineage Cell Therapeutics worth $9.7K as of Q3 2026.
Lineage Cell Therapeutics was a new Sigma Planning Corp position in Q3 2026.
Lineage Cell Therapeutics made up ﹤0.01% of Sigma Planning Corp's portfolio in Q3 2026, its #1323 holding.
57 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2026.

Based on Sigma Planning Corp's 13F filing for Q3 2026, filed 23 Oct 2026.